TUXEDO-2: Ticagrelor was not shown to be noninferior to prasugrel for the reduction of the primary composite endpoint of death, nonfatal #cvMI, stroke or major bleeding at one year in patients w/ diabetes & multivessel coronary disease undergoing #PCI. 👇 bit.ly/4b0SRdp

Systematic reviews in minutes to hours using artificial intelligence medrxiv.org/content/10.648… (caveat: thinly veiled advertisement for scholara.ai)

Decades of research show CAC as an accurate, cost-effective test to detect subclinical CAD. This #JACCIMG consensus from Drs. Naghavi, Fuster, et al calls on CMS to recognize CAC as a diagnostic test essential to personalized prevention. jacc.org/doi/10.1016/j.… #cvCAD #ASCVD

Original Article: Immediate or Deferred Nonculprit-Lesion PCI in Myocardial Infarction (iMODERN trial) nejm.org/doi/full/10.10… Editorial: Assessing Nonculprit Coronary-Artery Lesions in STEMI nejm.org/doi/full/10.10… #Cardiology

The Crochetage sign & ostium secundum ASD. ● Crochetage sign = Notching of the R wave at the apex of the R wave in the inferior leads on ECG. ● Seen in leads II, III, and aVF ● The notch resembles a “crochet hook”, which is why it is called crochetage (French for crochet).

Through ACC’s Cardiac #Amyloidosis online course, build confidence in recognizing the key symptoms & clinical clues of cardiac amyloidosis, selecting the right diagnostic tests & understanding treatment pathways. Learn more: bit.ly/3SCMPnL #ACCEd #AmyloidosisAwareness

Tirzepatide vs Semaglutide for MACE First real-world CV comparison of tirzepatide vs semaglutide in T2D with ASCVD. Two target-trial emulations addressing a question we've lacked data on until now. Deborah Wexler et al. diabetesjournals.org/care/article-a…

Our state-of-the-art review on pulmonary HTN due to left heart ds (group 2) now publ in JACC. Poor prognosis, esp when pre-capillary PH develops (PVR >2 WU - CpcPH). No specific Rx exist. We're starting the PULSE-LHD trial of PA denervation in 500 pts with group 2 PH and CpcPH.